CL2007001590A1 - Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica. - Google Patents
Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica.Info
- Publication number
- CL2007001590A1 CL2007001590A1 CL2007001590A CL2007001590A CL2007001590A1 CL 2007001590 A1 CL2007001590 A1 CL 2007001590A1 CL 2007001590 A CL2007001590 A CL 2007001590A CL 2007001590 A CL2007001590 A CL 2007001590A CL 2007001590 A1 CL2007001590 A1 CL 2007001590A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- parkinson
- pharmaceutical composition
- mpo
- copd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos derivados de tioxantina; composición farmacéutica; y uso en el tratamiento de desórdenes inflamatorios, neuroinflamatorios, tales como Parkinson, esclerosis múltiple, bronquitis, epoc, entre otras.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81091906P | 2006-06-05 | 2006-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007001590A1 true CL2007001590A1 (es) | 2008-01-25 |
Family
ID=38801720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2007001590A CL2007001590A1 (es) | 2006-06-05 | 2007-06-01 | Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica. |
Country Status (20)
Country | Link |
---|---|
US (2) | US7943625B2 (es) |
EP (1) | EP2029598A4 (es) |
JP (1) | JP2009539828A (es) |
KR (1) | KR20090014189A (es) |
CN (1) | CN101460498A (es) |
AR (1) | AR061134A1 (es) |
AU (1) | AU2007256005B2 (es) |
BR (1) | BRPI0712310A2 (es) |
CA (1) | CA2653774A1 (es) |
CL (1) | CL2007001590A1 (es) |
EC (1) | ECSP088965A (es) |
IL (1) | IL195287A0 (es) |
MX (1) | MX2008014991A (es) |
NO (1) | NO20085269L (es) |
RU (1) | RU2435772C2 (es) |
TW (1) | TW200804383A (es) |
UA (1) | UA94606C2 (es) |
UY (1) | UY30387A1 (es) |
WO (1) | WO2007142576A1 (es) |
ZA (1) | ZA200809800B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
TW200806667A (en) * | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
TW200804383A (en) * | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
US20090053176A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Combination 937 |
US20110144049A1 (en) * | 2009-10-21 | 2011-06-16 | Serebruany Victor L | Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke with Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof |
WO2012151576A1 (en) * | 2011-05-05 | 2012-11-08 | Robert Sackstein | Methods of treating complications and disorders associated with g-csf administration |
WO2013068875A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | 2-thiopyrimidinones |
US9221821B2 (en) | 2012-06-05 | 2015-12-29 | Forest Laboratories Holdings, Limited | Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds |
US9932329B2 (en) | 2014-03-03 | 2018-04-03 | Principia Biopharma, Inc. | Benzimidazole derivatives as RLK and ITK inhibitors |
WO2015196245A1 (en) * | 2014-06-25 | 2015-12-30 | Adelaide Research & Innovation Pty Ltd | Modulation of osteogenesis and or angiogenesis by modulating peroxidase functionality |
US9616063B2 (en) | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
WO2016178113A1 (en) | 2015-05-05 | 2016-11-10 | Pfizer Inc. | 2-thiopyrimidinones |
WO2016191172A1 (en) | 2015-05-22 | 2016-12-01 | Principia Biopharma Inc. | Quinolone derivatives as fibroblast growth factor receptor inhibitors |
TWI810582B (zh) | 2015-06-03 | 2023-08-01 | 美商普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
US20240166642A1 (en) | 2022-08-18 | 2024-05-23 | Astrazeneca Ab | Inhibitors of myeloperoxidase |
WO2024120457A1 (zh) * | 2022-12-09 | 2024-06-13 | 深圳信立泰药业股份有限公司 | 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3135753A (en) * | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
SE7810947L (sv) | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
GB8418430D0 (en) * | 1984-07-19 | 1984-08-22 | Beecham Wuelfing Gmbh & Co Kg | Treatment |
US4710503A (en) * | 1985-02-07 | 1987-12-01 | Euroceltique S.A. | 6-thioxanthine derivatives |
WO1989006125A1 (en) | 1987-12-31 | 1989-07-13 | Smithkline Beckman Corporation | 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols |
DK440989A (da) | 1988-09-12 | 1990-03-13 | Smithkline Beecham Corp | Dopamin-beta-hydroxylase inhibitorer |
JPH02160235A (ja) | 1988-12-13 | 1990-06-20 | Konica Corp | ハロゲン化銀カラー写真画像の形成方法 |
AU5436790A (en) * | 1989-04-19 | 1990-11-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Sulfer-containing xanthine derivatives as adenosin antagonists |
EP0430300A3 (en) | 1989-12-01 | 1992-03-25 | Takeda Chemical Industries, Ltd. | Xanthine derivatives, their production and use |
US5100906A (en) | 1990-04-19 | 1992-03-31 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers |
FR2665636B1 (fr) * | 1990-08-10 | 1994-10-07 | Adir | Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer. |
US6046019A (en) * | 1991-07-09 | 2000-04-04 | Goumeniouk; Alexander P. | Diagnostic kits and methods for making granulocyte cell counts |
US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
WO1995014681A1 (en) * | 1993-11-26 | 1995-06-01 | Pfizer Inc. | Isoxazoline compounds as antiinflammatory agents |
US5489598A (en) * | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
WO1996018400A1 (en) | 1994-12-13 | 1996-06-20 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
US6066641A (en) * | 1994-12-13 | 2000-05-23 | Euro-Celtique S.A. | Aryl thioxanthines |
US6025361A (en) * | 1994-12-13 | 2000-02-15 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
US5756511A (en) * | 1995-04-03 | 1998-05-26 | Cell Therapeutics, Inc. | Method for treating symptoms of a neurodegenerative condition |
US6294541B1 (en) * | 1996-06-06 | 2001-09-25 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
US5976823A (en) * | 1997-03-19 | 1999-11-02 | Integrated Biomedical Technology, Inc. | Low range total available chlorine test strip |
ATE325610T1 (de) | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6319928B1 (en) * | 1998-11-30 | 2001-11-20 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
DZ3019A1 (fr) | 1999-03-01 | 2005-05-20 | Smithkline Beecham Corp | Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd. |
JP2002541078A (ja) | 1999-04-02 | 2002-12-03 | ユーロ−セルティーク,エス.エー. | ホスホジエステラーゼiv阻害活性を有するプリン誘導体 |
GB2362101A (en) | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
FR2811989A1 (fr) | 2000-07-18 | 2002-01-25 | Sanofi Synthelabo | Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique |
EP1305328A2 (en) | 2000-07-21 | 2003-05-02 | Mark B. Lyles | Materials and methods for binding nucleic acids to surfaces |
FR2819723B1 (fr) * | 2001-01-23 | 2006-11-17 | Arnaud Mainnemare | Composition halogene, son procede de preparation et ses utilisations |
WO2002066447A1 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
SE0103766D0 (sv) * | 2001-11-09 | 2001-11-09 | Astrazeneca Ab | Novel assay |
DE60216442T2 (de) | 2001-05-08 | 2007-09-27 | Astrazeneca Ab | Test zum nachweis von inhibitoren des enzyms myeloperokidase |
ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
ES2208063B1 (es) | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
SE0301232D0 (sv) | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
SE0302756D0 (sv) | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
DE602004018808D1 (de) | 2003-10-31 | 2009-02-12 | Cv Therapeutics Inc | Antagonisten des a2b-adenosinrezeptors |
AU2005212816C1 (en) | 2004-02-14 | 2010-03-04 | Glaxosmithkline Llc | Novel compounds |
WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
SE0402591D0 (sv) | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
TW200806667A (en) * | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
TW200804383A (en) * | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
-
2007
- 2007-05-30 TW TW096119344A patent/TW200804383A/zh unknown
- 2007-05-31 AR ARP070102350A patent/AR061134A1/es not_active Application Discontinuation
- 2007-06-01 CL CL2007001590A patent/CL2007001590A1/es unknown
- 2007-06-01 US US11/756,967 patent/US7943625B2/en not_active Expired - Fee Related
- 2007-06-04 CN CNA2007800209903A patent/CN101460498A/zh active Pending
- 2007-06-04 KR KR1020087029646A patent/KR20090014189A/ko not_active Application Discontinuation
- 2007-06-04 US US12/300,673 patent/US20090131459A1/en not_active Abandoned
- 2007-06-04 MX MX2008014991A patent/MX2008014991A/es active IP Right Grant
- 2007-06-04 AU AU2007256005A patent/AU2007256005B2/en not_active Ceased
- 2007-06-04 BR BRPI0712310-8A patent/BRPI0712310A2/pt not_active IP Right Cessation
- 2007-06-04 JP JP2009514228A patent/JP2009539828A/ja active Pending
- 2007-06-04 WO PCT/SE2007/000537 patent/WO2007142576A1/en active Application Filing
- 2007-06-04 EP EP07748200A patent/EP2029598A4/en not_active Withdrawn
- 2007-06-04 UA UAA200813045A patent/UA94606C2/ru unknown
- 2007-06-04 CA CA002653774A patent/CA2653774A1/en not_active Abandoned
- 2007-06-04 UY UY30387A patent/UY30387A1/es unknown
- 2007-06-04 RU RU2008145971/04A patent/RU2435772C2/ru not_active IP Right Cessation
-
2008
- 2008-11-13 IL IL195287A patent/IL195287A0/en unknown
- 2008-11-17 ZA ZA200809800A patent/ZA200809800B/xx unknown
- 2008-12-12 EC EC2008008965A patent/ECSP088965A/es unknown
- 2008-12-16 NO NO20085269A patent/NO20085269L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200809800B (en) | 2010-04-28 |
UY30387A1 (es) | 2008-01-31 |
WO2007142576A1 (en) | 2007-12-13 |
RU2008145971A (ru) | 2010-07-20 |
JP2009539828A (ja) | 2009-11-19 |
UA94606C2 (ru) | 2011-05-25 |
NO20085269L (no) | 2009-03-05 |
KR20090014189A (ko) | 2009-02-06 |
BRPI0712310A2 (pt) | 2012-01-17 |
ECSP088965A (es) | 2009-01-30 |
US7943625B2 (en) | 2011-05-17 |
EP2029598A1 (en) | 2009-03-04 |
MX2008014991A (es) | 2008-12-05 |
AU2007256005B2 (en) | 2011-03-17 |
RU2435772C2 (ru) | 2011-12-10 |
IL195287A0 (en) | 2009-08-03 |
US20090131459A1 (en) | 2009-05-21 |
CN101460498A (zh) | 2009-06-17 |
AU2007256005A1 (en) | 2007-12-13 |
EP2029598A4 (en) | 2010-02-17 |
US20080221133A1 (en) | 2008-09-11 |
TW200804383A (en) | 2008-01-16 |
CA2653774A1 (en) | 2007-12-13 |
AR061134A1 (es) | 2008-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007001590A1 (es) | Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica. | |
CR9832A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
CL2007001972A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos. | |
CL2007003819A1 (es) | Compuestos derivados de isoquinolina e isoquinolinona; composicion farmaceutica; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, entre otras enfermedades. | |
MEP39508A (en) | Antagonist anti-cd40 antibody pharmaceutical compositions | |
CL2007003820A1 (es) | Compuestos derivados de isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, sida, entre otra | |
CL2011000663A1 (es) | Compuestos derivados de n-heterociclil-2-sulfonil acetamida, moduladores del receptor cb2, utiles para el tratamiento del dolor, enfermedad pulmonar, reumatica, autoinmune, entre otras. | |
BR112012033197A2 (pt) | métodos e composições para liberação de cns de n-sulfatase de heparano. | |
CL2008000911A1 (es) | Compuestos derivados de pirimidina, inhibidores de prostaglandina d2; composicion farmaceutica; y uso para tratar un trastorno alergico o inflamatorio tal como rinitis alergica, asma y epoc. | |
BR112015009913A2 (pt) | composições farmacêuticas para o tratamento de doenças mediadas por cftr | |
TN2012000512A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
ATE447568T1 (de) | Neue pyrinderivate | |
ATE489371T1 (de) | Benzamidglucokinaseaktivatoren | |
CL2008000404A1 (es) | Sal cristalina de napadisilato de 5-(2-[[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como asma o epoc. | |
DE602006014821D1 (de) | Ex-vivo-verfahren zur genzuführung | |
RS51185B (sr) | Kompozicije za vaginalnu primenu | |
WO2009002423A3 (en) | Polycyclic guanine derivatives and use thereof | |
CL2011001977A1 (es) | Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades. | |
EP3061824A3 (en) | Organic compositions to treat beta-enac-related diseases | |
EP1907014A4 (en) | CHONDROGENIC COMPOSITIONS AND METHODS OF USE | |
UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
HK1093746A1 (en) | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | |
CL2011000696A1 (es) | Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc | |
CL2007003754A1 (es) | Compuestos derivados de aril(heteroaril)alquil-amina; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como bronquitis, enfisema pulmonar y epoc. | |
CL2007003305A1 (es) | Compuestos analogos de adenosina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermdades tales como fibrosis quistica, otitis media, asma, ulcera peptica, entre otras. |